285 related articles for article (PubMed ID: 23327413)
1. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer.
Aurilio G; Monfardini L; Rizzo S; Sciandivasci A; Preda L; Bagnardi V; Disalvatore D; Pruneri G; Munzone E; Della Vigna P; Renne G; Bellomi M; Curigliano G; Goldhirsch A; Nolè F
Acta Oncol; 2013 Nov; 52(8):1649-56. PubMed ID: 23327413
[TBL] [Abstract][Full Text] [Related]
2. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
3. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
Aurilio G; Disalvatore D; Pruneri G; Bagnardi V; Viale G; Curigliano G; Adamoli L; Munzone E; Sciandivasci A; De Vita F; Goldhirsch A; Nolè F
Eur J Cancer; 2014 Jan; 50(2):277-89. PubMed ID: 24269135
[TBL] [Abstract][Full Text] [Related]
5. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
[TBL] [Abstract][Full Text] [Related]
6. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.
Amir E; Ooi WS; Simmons C; Kahn H; Christakis M; Popovic S; Kalina M; Chesney A; Singh G; Clemons M
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):763-8. PubMed ID: 18824337
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
8. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
9. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
10. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?
Wang N; Wang B; Wang Y; Hu J
Breast; 2011 Dec; 20(6):519-24. PubMed ID: 21700456
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
Chen X; Yuan Y; Gu Z; Shen K
Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
[TBL] [Abstract][Full Text] [Related]
14. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
[TBL] [Abstract][Full Text] [Related]
15. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
[TBL] [Abstract][Full Text] [Related]
16. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
[TBL] [Abstract][Full Text] [Related]
17. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
20. Receptor expression discrepancy between primary and metastatic breast cancer lesions.
Karagöz Özen DS; Ozturk MA; Aydin Ö; Turna ZH; Ilvan S; Özgüroglu M
Oncol Res Treat; 2014; 37(11):622-6. PubMed ID: 25427579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
